Detected ·
NUCLIDIUM AG
——
Clinical-stage radiopharmaceutical company NUCLIDIUM AG closed its Series B extension, bringing the total round to CHF 105 million (~€114 million). The company is developing a proprietary copper-based platform to diagnose and treat cancer, with lead programs targeting metastatic prostate cancer and metastatic breast cancer.
- Website
- nuclidium.com
- linkedin.com/company/nuclidium
- Amount
- —
- Stage
- —
- Event
- Funding round
- Detected
- 2026-05-27 12:07:11 UTC
- Signal ID
- cf90db63-e2d2-418f-a736-228fa04c4216
As the API returns it
{
"id": "cf90db63-e2d2-418f-a736-228fa04c4216",
"created_at": "2026-05-27T12:07:11.418528Z",
"company_name": "NUCLIDIUM AG",
"company_website_url": "nuclidium.com",
"company_linkedin_url": "https://www.linkedin.com/company/nuclidium",
"event_type": "funding",
"funding_amount": null,
"funding_currency": null,
"funding_stage": null,
"message": "*Clinical-stage radiopharmaceutical company NUCLIDIUM AG closed its Series B extension, bringing the total round to CHF 105 million (~€114 million). The company is developing a proprietary copper-based platform to diagnose and treat cancer, with lead programs targeting metastatic prostate cancer and metastatic breast cancer.*"
}